Abstract 2096P
Background
The National Comprehensive Cancer Network (NCCN) guideline recommend starting with opioids for severe cancer pain or pain crisis. In this case, short-acting oral opioids or injections can be considered and drug titration should be performed by re-evaluating after 1 hour for oral drugs and after 15 minutes for injections. However, in actual medical practice, it's challenging to promptly administer injections and perform dose titration through pain assessment every 15 minutes. Patient-controlled analgesia (PCA) is a recommended method that enables patients to self-administer medication, potentially reducing the time required for medication administrations, but there are limited studies on this.
Methods
Patients with cancer pain with an average NRS (Numeric Rating Scale) score of 7 or higher within the last 24 hours were enrolled from 3 centers. The patients who were taking opioids with a morphine equivalent daily dose of 300 mg/day or higher were excluded. Patients complete a pain diary at baseline, 1, 2, 4, 12, 24, and 48 hours. The researchers monitor side effects and conduct a brief pain assessment at 24 and 48 hours. Patients also record their Patient Global Impression of Change (PGI-C) at 24 and 48 hours. The endpoint of this study is percentage of patients with a pain NRS score of 3 or less one hour after PCA application.
Results
Between August 2021 and April 2023, a total of 38 patients were enrolled in the study, with 37 completing and 1 dropout. Of these, 8 (21%) were opioid-naive and 29 (76%) were opioid-tolerant. Within 1 hour, 26 patients (68%) reached NRS 3 or lower pain control. And in a 24-hour PGI-C, 26 patients (63%) reported their condition as very much or much improved. The 33 patients (87%) had no adverse events during the study. Four patients experienced side effects, such as nausea and vomiting; three were mild and one was moderate. No serious adverse events (SAEs) were reported. A possible association between the medication and symptoms was observed in two patients, whereas for the other two, it was assessed to be unlikely.
Conclusions
Effective pain management through dose titration is crucial in the treatment of severe cancer pain. The study confirmed that PCA-based pain control was highly effective, safe, and satisfactory for patients.
Clinical trial identification
DAUHIRB-21-125.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
BC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06